Hepion Pharmaceuticals Shares Outstanding vs. Debt To Equity

HEPA Stock  USD 0.66  0.03  4.35%   
Based on Hepion Pharmaceuticals' profitability indicators, Hepion Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Hepion Pharmaceuticals' ability to earn profits and add value for shareholders. At present, Hepion Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Average Payables is expected to grow to about 2.6 M, whereas Book Value Per Share is forecasted to decline to 1.74.
For Hepion Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hepion Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hepion Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hepion Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hepion Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.40)
Return On Assets
(0.93)
Return On Equity
(1.90)
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hepion Pharmaceuticals Debt To Equity vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hepion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hepion Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Hepion Pharmaceuticals is rated below average in shares outstanding category among its peers. It is rated # 5 in debt to equity category among its peers . The ratio of Shares Outstanding to Debt To Equity for Hepion Pharmaceuticals is about  6,958,370,000 . At present, Hepion Pharmaceuticals' Debt To Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hepion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Hepion Debt To Equity vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Hepion Pharmaceuticals

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
6.96 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Hepion Pharmaceuticals

D/E

 = 

Total Debt

Total Equity

 = 
0 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Hepion Debt To Equity Comparison

Hepion Pharmaceuticals is currently under evaluation in debt to equity category among its peers.

Hepion Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hepion Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hepion Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Hepion Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Hepion Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-78.8 K-74.8 K
Operating Income-48.4 M-46 M
Income Before Tax-49.3 M-46.9 M
Total Other Income Expense Net-887.1 K-842.8 K
Net Loss-48.9 M-46.5 M
Income Tax Expense409 K429.5 K
Net Loss-40.8 M-38.8 M
Interest Income158.3 K150.4 K
Net Loss-44.7 M-42.4 M
Net Interest Income-9.6 K-10 K
Change To Netincome4.6 M4.8 M
Net Loss(12.32)(12.94)
Income Quality 0.84  0.66 
Net Income Per E B T 0.99  0.74 

Hepion Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hepion Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hepion Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hepion Pharmaceuticals' important profitability drivers and their relationship over time.

Use Hepion Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hepion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hepion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Hepion Pharmaceuticals Pair Trading

Hepion Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Hepion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hepion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hepion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hepion Pharmaceuticals to buy it.
The correlation of Hepion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hepion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hepion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hepion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Hepion Pharmaceuticals position

In addition to having Hepion Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Insurance Thematic Idea Now

Insurance
Insurance Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:
Check out Risk vs Return Analysis.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Hepion Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Hepion Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Hepion Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Hepion Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Hepion Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Hepion Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Hepion Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.